Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sagent-Hengrui Partnership Launches Second Cancer Drug in US

publication date: Sep 26, 2014
Sagent Pharma announced the second US launch of a product from its partnership with Hengrui Medicine . The drug is Oxaliplatin Injection, USP, a treatment for colon and rectal cancer, which has a US market of $102 million, according to IMS. Hengrui will manufacture the drug. Last month, Sagent began US marketing of Hydrochloride Injection, another Hengrui-produced treatment for cancer.  More details....

Stock Symbols: (NSDQ: SGNT) (SHA: 600276)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital